Macrophage Models For Tuberculosis Studies, A Systematic Review And Meta-Analysis Study
Abstract
Setting: Macrophage models create an environment for the growth of mycobacterium tuberculosis and can be applied to studies on the intracellular pathogen.
Objective: To review macrophage models for tuberculosis studies in terms of the cell sources and applications.
Methods: The online English database PubMed, Chinese databases such as CNKI, SinoMed, and Wanfang were searched up to December 2010 for published articles. Two groups of terms were used for the information retrieval, one of which includes macrophage model and macrophage; the other group of terms comprises mycobacterium tuberculosis. For PubMed, the two groups of English terms were applied, while for the Chinese databases, related Chinese terms were used.
Results: Cell sources of macrophage models include murine bone marrows, human peripheral blood, human lungs, and cell lines. The screened antituberculosis drugs are Western drugs such as ciprofloxacin and ofloxacin, and traditional Chinese medications like pittosporum brevicalyx (oliv.) gagnep and Ranunculus ternatus thunb. The regulation of SigB and SigF was described in the pathogenesis of tuberculosis, while pknE mutant modifying the innate immune response in immuno-mechanism of tuberculosis.
Conclusions: There are four major cell sources for developing a macrophage model, which can be applied to studies on screening both Western and Chinese anti-TB drugs, figuring out the pathogenesis and immune-mechanism of TB with some key issues remaining to be dealt with.
Downloads
References
Lee JH, Karakousis PC, Bishai WR. Roles of SigB and SigF in the Mycobacterium tuberculosis sigma factor network. J Bacteriol. 2008 Jan; 190(2):699-707. Epub 2007 Nov 9.
Xie Jianping, Li Yao, Yue Jun, Xue Yongzhong, Huang Daqiang, Liang Li, Wang Honghai. Exploring Mycobacterium tuberculosis infection-induced alterations in gene expression in macrophage by microarray hybridization. Science in China. Series C, Life sciences.2003, 46(4): 337-347.
Slayden RA, Lee RE, Armour JW, Cooper AM, Orme IM, Brennan PJ, Besra GS.Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother. 1996 Dec; 40(12):2813-9.
Zhao BY, Pine R, Domagala J, Drlica K.Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother. 1999 Mar; 43(3):661-6.
Eddine AN, von Kries JP, Podust MV, Warrier T, Kaufmann SH, Podust LM.X-ray Structure of 4,4′-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14α-Demethylase (CYP51). J Biol Chem. 2008 May 30; 283(22): 15152–15159.
Skinner PS, Furney SK, Jacobs MR, Klopman G, Ellner JJ, Orme IM.A Bone Marrow-Derived Murine Macrophage Model for Evaluating Efficacy of Antimycobacterial Drugs under Relevant Physiological Conditions. Antimicrob Agents Chemother. 1994 Nov; 38(11):2557-63.
Pichugin AV, Yan BS, Sloutsky A, Kobzik L, Kramnik I.Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts. Am J Pathol. 2009 Jun; 174(6):2190-201. Epub 2009 May 14.
Bashir N, Kounsar F, Mukhopadhyay S, Hasnain SE.Mycobacterium tuberculosis conserved hypothetical protein rRv2626c modulates macrophage effector functions. Immunology. 2010 May; 130(1):34-45. Epub 2010 Feb 26.
Nair S, Ramaswamy PA, Ghosh S, Joshi DC, Pathak N, Siddiqui I, Sharma P, Hasnain SE, Mande SC, Mukhopadhyay S. The PPE18 of Mycobacterium tuberculosis interacts with TLR2 and activates IL-10 induction in macrophage. J Immunol. 2009 Nov 15; 183(10):6269-81. Epub 2009 Oct 30.
Esquivel-SolÃs H, Quiñones-Falconi F, Zarain-Herzberg A, Amieva-Fernández RI, López-Vidal Y.Impaired activation of Stat1 and c-Jun as a possible defect in macrophages of patients with active tuberculosis. Clin Exp Immunol. 2009 Oct; 158(1):45-54.
Alam K, Ghousunnissa S, Nair S, Valluri VL, Mukhopadhyay S.Glutathione-redox balance regulates c-rel-driven IL-12
production in macrophages: possible implications in antituberculosis immunotherapy. J Immunol. 2010 Mar 15; 184(6):2918-29. Epub 2010 Feb 17.
Juarez E, Nuñez C, Sada E, Ellner JJ, Schwander SK, Torres M.Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res. 2010 Jan 5; 11:2.
Tominaga T, Suzuki M, Saeki H, Matsuno S, Tachibana T, Kudo T. Establishment of an activated macrophage cell line, A-THP-1, and its properties. Tohoku J. Exp. Med. 1998 Oct; 186(2):99-119.
Bai X, Kim SH, Azam T, McGibney MT, Huang H, Dinarello CA, Chan ED.IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol. 2010 Apr 1; 184(7):3830-40. Epub 2010 Feb 26.
Crowle AJ. Studies of antituberculosis chemotherapy with an in vitro model of human tuberculosis. Semin Respir Infect. 1986 Dec;1(4):262-4.
Rastogi N, Blom-Potar MC. Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line. Zentralbl Bakteriol. 1990 Jun; 273(2):195-9.
Sbarbaro JA, Iseman MD, Crowle AJ. The combined effect of rifampin and pyrazinamide within the human macrophage. Am Rev Respir Dis. 1992 Dec; 146(6):1448-51.
Furney SK, Skinner PS, Farrer J, Orme IM. Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. Antimicrob Agents Chemother. 1995 Mar; 39(3):786-9.
Sbarbaro JA, Iseman MD, Crowle AJ. Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuber Lung Dis. 1996 Dec; 77(6):491-5.
Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1996 Dec; 40(12):2809-12.
Phetsuksiri B, Baulard AR, Cooper AM, Minnikin DE, Douglas JD, Besra GS, Brennan PJ.Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob Agents Chemother. 1999 May; 43(5):1042-51.
Szymańska E, Kieć-Kononowicz K. Antimycobacterial activity of 5-arylidene aromatic derivatives of hydantoin. Farmaco. 2002 May; 57(5):355-62.
Foroumadi A, Soltani F, Mirzaei M. Antituberculosis agents IV: in vitro antimycobacterial activity and cytotoxicity of N-piperazinyl quinolone derivatives containing 2-thienyl and 2-furyl moiety. Pharmazie. 2003 May; 58(5):347-8.
Qian Zhongqing. Studies on Use of Containing Medicine Serum and Infected Mφ Model in Evaluation of Activity of Anti-Mycobacterium Tuberculosis Medicine [master thesis]. Kunming: Kunming Medical University; 2004.
Maccari R, Ottanà R, Bottari B, Rotondo E, Vigorita MG. In vitro advanced antimycobacterial screening of cobalt (II) and copper (II) complexes of fluorinated isonicotinoylhydrazones. Bioorg Med Chem Lett. 2004 Dec 6; 14(23):5731-3.
Maccari R, Ottanà R, Vigorita MG. In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14. Bioorg Med Chem Lett. 2005 May 16; 15(10):2509-13.
Ma C, Case RJ, Wang Y, Zhang HJ, Tan GT, Van Hung N, Cuong NM, Franzblau SG, Soejarto DD, Fong HH, Pauli GF. Anti-tuberculosis constituents from the stem bark of Micromelum hirsutum. Planta Med. 2005 Mar; 71(3):261-7.
Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. Antimicrob Agents Chemother. 2007 Oct; 51(10):3562-7. Epub 2007 Jul 30.
Singh RP, Jhamb SS, Singh PP. Effects of morphine during Mycobacterium tuberculosis H37Rv infection in mice. Life Sci. 2008 Jan 30; 82(5-6):308-14.
Wu Guodong, Zhang Caijun, Wang Ling, Wu Lei, Cun Xinhua, Cao Xia.Experimental Study on Macrophage Model for Screening Natural Antituberculous Drugs. Journal of Kunming Medical University. 2010; (11):4-7+24.
Horgen L, Jerome A, Rastogi N.Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. Antimicrob Agents Chemother. 1998 Nov; 42(11):3006-8.
Jayakumar D, Jacobs WR Jr, Narayanan S.Protein kinase E of Mycobacterium tuberculosis has a role in the nitric oxide stress response and apoptosis in a human macrophage model of infection. Cell Microbiol. 2008 Feb; 10(2):365-74. Epub 2007 Sep 24.
Basler T, Geffers R, Weiss S, Valentin-Weigand P, Goethe R.Mycobacterium avium subspecies induce differential expression of pro-inflammatory mediators in a murine macrophage model: evidence for enhanced pathogenicity of Mycobacterium avium subspecies paratuberculosis. Immunobiology. 2008; 213(9-10):879-88. Epub 2008 Sep 2.
Meena LS, Rajni. Survival mechanisms of pathogenic Mycobacterium tuberculosis H37Rv. FEBS J. 2010 Jun; 277(11):2416-27.
Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci U S A. 2010 May 25; 107(21):9819-24.
Bordbar A, Lewis NE, Schellenberger J, Palsson BØ, Jamshidi N. Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions. Mol Syst Biol. 2010 Oct 19; 6:422.
Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, Kuchroo VK, Behar SM.Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med. 2010 Oct 25; 207(11):2343-54. Epub 2010 Oct 11.
Copyright (c) 2015 Bulletin of Advanced Scientific Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms: a) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
